CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER
Mast Cell Leukemia
Explore 10 assets in Mast Cell Leukemia →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
GT Biopharma, Inc.
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03214666CT.gov GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mast Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER (this asset) | GT Biopharma, Inc. | P1/2 | CCC · 48 |
| Cyclosporin A | Stanford University | P2 | BB |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Avapritinib | Blueprint Medicines Corporation | P2 | BB |
| Brentuximab Vedotin | Jason Robert Gotlib | P2 | B |
| Nivestim | Stanford University | P2 | B |
| Hydrocortisone | Stanford University | P2 | B |
| Rituximab | Stanford University | P2 | B |
| Granisetron | Stanford University | P2 | B |
+16 more in the Mast Cell Leukemia cohort
Other indications for CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic Syndrome | — | P1/2 | CCC · 48 |
| Systemic Mastocytosis | — | P1/2 | CCC · 48 |
| Acute Myeloid Leukemia | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER in Mast Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd16il15cd33-trispecific-killer-cell-engager-mast-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →